Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

PennyMac investigated for allegedly misrepresenting mortgage refinancing success, causing stock to plunge 37%.

Market News
10 Jun 2026
GlobeNewsWire
View Source
Bearish
pluang ai news

PennyMac Financial Services is under investigation by law firm Bleichmar Fonti & Auld for potentially misleading investors about its ability to retain mortgage refinancing customers. The company had increased its loan origination capacity to capture more refinance business as interest rates fell, but later revealed that intense competition limited its success. This disclosure led to a 37% drop in PennyMac's stock price in January 2026. Investors who suffered losses may have legal options and are encouraged to contact the law firm for representation.

More News

Hamanasi Resort in Belize named #1 hotel in Central America and #15 worldwide by Tripadvisor in 2026.

Hamanasi Resort in Belize named #1 hotel in Central America and #15 worldwide by Tripadvisor in 2026.

Hamanasi Adventure & Dive Resort in Belize was ranked the #1 hotel in Central America and #15 globally in the 2026 Tripadvisor Travelers’ Choice Best of the Best Awards. This prestigious recognition is based on exceptional guest reviews and highlight...

Others
Neutral
21 minutes ago
US government buys 10% stake in mining firms, signaling a new strategic investment trend.

US government buys 10% stake in mining firms, signaling a new strategic investment trend.

In early 2026, the US government began acquiring stakes in American mining companies, including a 10% share in USA Rare Earth to support critical mineral projects. This move follows similar investments in Lithium Americas and Trilogy Metals, which sa...

Market News
Bullish
29 minutes ago
FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.

FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.

The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin produc...

Market News
Bullish
2 hours ago
FDA approves Sanofi's Tzield as first disease-modifying therapy for newly diagnosed stage 3 type 1 diabetes in children.

FDA approves Sanofi's Tzield as first disease-modifying therapy for newly diagnosed stage 3 type 1 diabetes in children.

The FDA granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). Tzield slows the decline of the body's insulin production by targeting the autoimmune process c...

Market News
Bullish
2 hours ago
Heartland Express declares $0.02 quarterly dividend, continuing 92 quarters of payouts.

Heartland Express declares $0.02 quarterly dividend, continuing 92 quarters of payouts.

Heartland Express, Inc. announced a regular quarterly cash dividend of $0.02 per share, payable on July 6, 2026, to shareholders of record as of June 23, 2026. This marks the company's 92nd consecutive quarterly dividend, with a total payout of $564....

Company Fundamentals
Neutral
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App